These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38332525)

  • 21. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
    Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
    AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.
    Manne-Goehler J; Fabian J; Sokhela S; Akpomiemie G; Rahim N; Lalla-Edward ST; Brennan AT; Siedner MJ; Hill A; Venter WDF
    J Int AIDS Soc; 2024 Jul; 27(7):e26268. PubMed ID: 38978403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
    Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
    BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
    AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda.
    Nuwamanya E; Nassiwa SC; Kuznik A; Waitt C; Malaba T; Myer L; Colbers A; Read J; Wang D; Lamorde M
    Value Health Reg Issues; 2024 Nov; 44():101017. PubMed ID: 38905817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch to dolutegravir is well tolerated in Thais with HIV infection.
    Goh OQ; Colby DJ; Pinyakorn S; Sacdalan C; Kroon E; Chan P; Chomchey N; Kanaprach R; Prueksakaew P; Suttichom D; Trichavaroj R; Spudich S; Robb ML; Phanuphak P; Phanuphak N; Ananworanich J;
    J Int AIDS Soc; 2019 Jul; 22(7):e25324. PubMed ID: 31294931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
    Griesel R; Maartens G; Chirehwa M; Sokhela S; Akpomiemie G; Moorhouse M; Venter F; Sinxadi P
    Clin Infect Dis; 2021 Dec; 73(11):e3902-e3909. PubMed ID: 32960272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.
    Griesel R; Kawuma AN; Wasmann R; Sokhela S; Akpomiemie G; Venter WDF; Wiesner L; Denti P; Sinxadi P; Maartens G
    Br J Clin Pharmacol; 2022 Mar; 88(3):883-893. PubMed ID: 34954840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
    Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
    BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.
    Nightingale S; Dreyer AJ; Thomas KGF; van Zyl G; Decloedt E; Naude PJW; Orrell C; Sinxadi P; Winston A; Khoo S; Joska JA
    Lancet HIV; 2024 Oct; 11(10):e680-e689. PubMed ID: 39284338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
    George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
    Front Immunol; 2021; 12():639378. PubMed ID: 34093527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study.
    Roux CG; Mason S; du Toit LDV; Nel JG; Rossouw TM; Steel HC
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
    Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
    J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.